Silverarc Capital Management LLC trimmed its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 32.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,788 shares of the company's stock after selling 19,712 shares during the period. Silverarc Capital Management LLC's holdings in Vaxcyte were worth $3,339,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares in the last quarter. National Bank of Canada FI bought a new position in shares of Vaxcyte in the 4th quarter valued at $41,000. Blue Trust Inc. lifted its position in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. boosted its stake in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after buying an additional 775 shares in the last quarter. 96.78% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several research analysts have commented on the company. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and an average price target of $136.50.
Read Our Latest Report on Vaxcyte
Vaxcyte Price Performance
NASDAQ PCVX traded down $1.59 on Friday, reaching $32.92. The company had a trading volume of 1,638,022 shares, compared to its average volume of 1,234,781. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of -7.16 and a beta of 1.26. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The business has a 50 day moving average of $55.57 and a two-hundred day moving average of $80.12.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. As a group, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
Insider Activity
In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,180,820.35. The trade was a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 24,000 shares of company stock valued at $1,946,720. 3.10% of the stock is currently owned by insiders.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
